| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_17fa43dc284f1ba778e001132b1f7098 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7016
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-568
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7016
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-569 |
| filingDate |
2018-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6112d311c28ddcf96b3726efc3cab7c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de60f9163ed6dc80517209a00335671f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3b28250af107cc7a9b0c2097e0deba7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a0343266e291971d7825280814dbbf4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0cd7d54255d227c8f10197a28504b8f7 |
| publicationDate |
2020-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2018374029-A1 |
| titleOfInvention |
Pharmaceutical formulation of 3a-ethynyl-3B-hydroxyandrostan-17-one oxime |
| abstract |
The present invention is directed to a novel pharmaceutical formulation comprising 3α-ethynyl-3β- hydroxyandrostan-17-one oxime in an amount of 0.1-10 % by weight of the total weight of the composition; and a vehicle comprising (a) 45-100 % of a monoester; (b) optionally up to 51 % of a diester; and (c) optionally up to about 10 % of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepathic encephalopathy by the use of a pharmaceutical formulation as claimed. |
| priorityDate |
2017-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |